Cell penetrating peptide: A potent delivery system in vaccine development.

Front Pharmacol · 2022 · PMC9679422 · PMID 36425579

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

However, there are just a few approved adjuvants, and their immunostimulatory activity is frequently limited, while their toxicity might be significant ( Nevagi et al., 2018 ).

also in 2,435 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.